There are limited data regarding the molecular characterization of undifferentiated pleomorphic sarcomas (UPS; formerly malignant fibrous histiocytoma). This study aimed to investigate the utility of next generation sequencing (NGS) in UPS to identify subsets of patients who harbour actionable mutations. Patients diagnosed with UPS underwent pathological reevaluation by a pathologist specializing in sarcoma. Tumor DNA was isolated from archived fresh frozen tissue samples and genotyped using NGS with the Illumina MiSeq TruSeq Amplicon Cancer Panel (48 genes, 212 amplicons). In total, 95 patients initially classified with UPS were identified. Following pathology re-review the histological subtypes were reclassified to include: Myxofibrosarcoma (MFS, N 5 44); UPS(N 5 18); and Others (N 5 27; including undifferentiated spindle cell sarcoma (N 5 15) and dedifferentiated liposarcoma (N 5 6)). Seven cases were excluded from further analysis for other reasons. Baseline demographics of the finalized cohort (N 5 88) showed a median age of 66 years (32-95), primarily with stage I-III disease (92%) and high-grade (86%) lesions. Somatic mutations were identified in 31 cases (35%)(Total mutations 5 36: solitary mutation(n 5 27); two mutations( 5n 5 3); three mutations(n 5 1)). The most commonly identified mutations were in TP53 (n 5 24), ATM (n 5 3) and PIK3CA (n 5 2). Three of 43 patients with MFS and one of 18 patients with UPS had clinically relevant mutations, mainly related to biomarkers of prediction of response; however few had targetable driver mutations. Somatic mutation status did not influence disease free or overall survival. Based on the small number of clinically relevant mutations, these data do not support the routine use of targeted NGS panels outside of research protocols in UPS.
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Soft tissue sarcomas (STS) are a heterogeneous group of tumors of mesenchymal origin and represent approximately 1% of adult cancers. 1 Advances in molecular testing have provided significant insights into the biological drivers of these rare cancers which has prompted the incorporation of molecular data into the current classification of these tumors. 2, 3 One of the most common subtypes of STS is undifferentiated pleomorphic sarcoma (UPS), previously known as malignant fibrous histiocytoma (MFH). 4 These tumors are characterized by a lack of an overt line of differentiation and classically represent a diagnosis of exclusion once potential histologic mimics have been excluded (e.g. dedifferentiated liposarcoma). 5, 6 UPS is typically a large, deep-seated and high-grade tumor. Compared to other STS, it also carries a poorer prognosis with five-year survival rates ranging between 30% and 50%. 7 In the metastatic setting, the limited and lack of durable response to first line cytotoxic chemotherapy underlies the critical need to identify new and novel agents for this STS subtype.
STS can be divided into those with basic genomic alterations (e.g. simple karyotypes, translocations or activating mutations) or complex lesions 8, 9 with numerous patternless genetic aberrations. 10, 11 This second group, in which UPS is considered, is heterogenous and characterized by complex karyotypes 10 with underlying dysregulation of cell cycling, disruption of tumor suppressor pathways and inhibition of signal transduction. [12] [13] [14] [15] [16] However, only limited genomic analyses in UPS have been conducted 13, 14, 17, 18 and no specific molecular event has been defined. Understanding the molecular characteristics of UPS is critical towards understanding its inherent biology as it may potentially allow the development and application of molecularly targeted agents. Targeted therapies aim to directly inhibit a specific molecular aberration in the hope of increasing effectiveness and reducing toxicity. 19 Although several examples of targeted therapies in sarcoma have been identified (e.g. cKIT inhibitors in dermatofibrosarcoma protuberans 20 and gastrointestinal stromal tumors, 21 RANKL antagonists in giant cell tumor of bone, 22 CSF-1 R inhibition in pigmented villonodular synovitis 23 ), most subtypes of STS are treated with standard cytotoxic chemotherapies which carry limited effectiveness and high toxicity. High-throughput screening for targetable mutations in UPS is lacking. Next generation sequencing (NGS) is a technique that allows an efficient and cost-effective genomic analysis. 24 In this study, we retrospectively investigated patients with UPS showing the diagnostic evaluation of this entity and present molecular characterization using NGS with the aim of identifying clinically actionable driver mutations.
MATERIAL AND METHODS

Patients
Tumor samples from the primary extremity site of 95 patients diagnosed with UPS after the year 1988 were identified from a clinical sarcoma database at Mount Sinai Hospital (MSH). After institutional Research Ethics Board approval, samples were collected from the MSH Clinical Core and Sarcoma Biospecimen Repository. Clinical data were abstracted from all patients including age, tumor characteristics (stage, grade, size, depth), disease free survival (DFS) and overall survival (OS).
Pathology review
Of the 95 identified cases of UPS, all available slides were retrieved from the departmental archives for re-review. Three cases had insufficient lesional tissue available for definitive classification, and were therefore excluded from further analysis. A review of each of the remaining 92 cases was conducted by a pathologist specializing in sarcoma using the criteria detailed in the current WHO classification of tumors of soft tissue and bone. 3 In some cases, considerable time had elapsed since the initial diagnosis; as a result, interval advances in morphologic criteria, immunohistochemistry and molecular assays [i.e., fluorescence in situ hybridization (FISH) and polymerase chain reaction (PCR)] were rigorously applied. For example, RT-PCR was applied in each case to exclude the presence of MDM2 amplification which would otherwise suggest a diagnosis of dedifferentiated liposarcoma.
Specimens
Fresh frozen archived tumor samples were used for DNA extraction. Tumors were manually macrodissected from unstained tissue sections and genomic tumor DNA was extracted using the QIAamp DNA mini kit as recommended by the manufacturer (Qiagen, Germantown, MD). Peripheral blood samples were not available as internal control as this was not routinely collected at the time of this study as part of the Biospecimen Repository.
Genomic assays
All testing for this study was performed in Biosoftware, Rouen, France) and Integrative Genomics Viewer (IGV, Broad Institute).
Variant calling and somatic variant classification
Variants that were reported met the predefined quality read depth coverage threshold of 5003 coverage. Variants were classified according to the somatic variant classification scheme described in Sukhai et al. 25 Briefly, this scheme classifies somatic variants into five major classes (1, 2, 3, 4 and 5) based on the following criteria: prevalence, pathogenicity and actionability (Supporting Information Table  2 ). "Actionability" was the most critical assessor of the variant class, with actionability defined as the prognostic, predictive, diagnostic or druggability score of a particular variant or gene in a tumor site. Class 1 and 2 variants are the most clinically significant, with Class 1 variants known to be actionable in the tumor site/histology indicated for the patient, and Class 2 variants known to be actionable at a tumor site other than that found in that particular patient. Variants were labelled as Class 3 or 4 if sufficient information was not available for the specific variant, but the gene is actionable in the tumor site/histology of interest (Class 3) or at a different tumor site/histology (Class 4). If nothing was known about the gene or the variant then the variant was classified as Class 5 variant. Class 3 and 4 were further subclassified as A, B or C based on the "pathogenicity" of a particular variant as per evidence (in vitro and in vivo experimental studies, in silico prediction algorithms, preclinical studies and early phase clinical trials). The term "pathogenicity" referred to the deleterious effect of a variant on protein function-if deleterious-it was considered an A, if unknown then B and if benign then C.
Somatic variant subclassification
Two alternative uses of the somatic variant classification system described above were undertaken, because of the relative lack of information in the literature with regards to molecular characterization in subgroups of STS (Nonstandard Classification and Standard Classification). Nonstandard Classification included limited or unvalidated studies in STS assessing biomarkers of response whereas Standard Classification excluded these studies and classified clinical utility only if variants had been described in other tumor types. In addition, germline mutations described on external databases were factored into the Standard Classification.
Classification of possible germline variants
Certain variants identified in tumor samples in this study had been recorded as germline variants in the Princess Margaret Cancer Centre internal variant database, based on previous matched tumor-normal NGS-based mutational profiling for other studies, as control DNA samples were not available. For these putative germline variants, classification was performed using five classes: pathogenic, likely pathogenic, benign, likely benign or variant of uncertain significance (VOUS) as per ACMG guidelines for germline variants. 26 
Statistical analysis
Categorical and ordinal data are described with the use of frequencies. Patient age and the follow-up times are expressed as medians together with the minimum and maximum values. Time to event analysis was estimated using the Kaplan-Meier product limit method. Comparisons between mutational status and DFS or OS were investigated using the log-rank test and Cox proportional hazards regression for the following variables: age, tumor depth, tumor grade and maximum dimensions. A p value of <0.05 was considered statistically significant. Statistical analysis was performed using Excel (Microsoft, Redmond, WA, USA), GraphPad Prism 6 (Graphpad Software, La Jolla, CA, USA) and R version 2. 
RESULTS
Patient characteristics
In total, 95 patients with an initial diagnosis of UPS were screened. Several nonsarcoma cases were excluded: aneurysmal bone cyst (N 5 1), undifferentiated carcinoma (N 5 1) and a desmoplastic melanoma (N 5 1). Three other cases were excluded for lack of available slides or paraffin blocks. The results of pathology review of the remaining 89 patients are detailed in Table 1 . A majority of cases fulfilled the criteria for myxofibrosarcoma (MFS)(N 5 44): this observation is not surprising as many had been originally classified as socalled myxoid-MFH. The next major category was that of undifferentiated STS (USTS; N 5 33). In accordance with the WHO, 3 these cases were subdivided morphologically; they included UPS (N 5 18) and undifferentiated spindle cell sarcoma (USSS; N 5 15). Other categories identified were six cases that were re-classified as dedifferentiated liposarcoma based on the presence of MDM2 amplification, soft tissue osteosarcoma (N 5 3), low-grade fibromyxoid sarcoma (N 5 1), epithelioid sarcoma (N 5 1) and rhabdomyosarcoma (N 5 1). One tumor sample with MFS had minimal viable tumor and was not molecularly characterized leaving a final cohort of 88 patients.
Baseline demographics of the finalized cohort (n 5 88) is shown in Table 2 . The median age was 66 years (range: 32-95) with females comprising 40% and 64% occurring in the lower limb. The majority of patients had stage I-III disease (92%), high-grade (86%) and deep lesions (77%).
Mutation status
Mutational characterization revealed that 31 of 88 patients (35%) had at least one somatic mutation (total mutations 5 36: solitary mutation (n 5 27); two mutations (n 5 3); three mutations (n 5 1)). Divided by subgroup, mutations were identified 22 times in 43 patients with MFS, four mutations in 18 patients with UPS and 10 mutations in 27 patients in the "Other" group. In the "Other" group, no mutations were identified in patients with dedifferentiated liposarcoma (n 5 6) or in the solitary patients with epithelioid sarcoma and low-grade fibromyxoid sarcoma. Mutations were identified more frequently in patients who were disease free (Total Group 41%: MFS 50%; UPS 27%; Other 36%) as compared to those with relapsed disease (Total Group 29%: MFS 32%; UPS 14%; Other 33%). The most commonly identified mutations across all subgroups were in TP53 (n 5 24), ATM (n 5 3) and PIK3CA (n 5 2). Solitary mutations were identified in FBXW7, PTEN, ERBB4, SMAD4, FGFR1, KIT and NRAS. Division of mutation per histological subgroup are presented in Table 3 and Figure 1 . After review with database variant classifiers (e.g. ClinVAR, OMIM, ESP, dbSNP and our internal PMCC database), several solitary mutations identified were considered as germline benign or VOUS (N 5 6; ABL1, AKT1, APC, ATM (two cases) and MET). Clinically actionable mutations (as defined by Class 1 or 2 mutations) were present in eight (19%) of cases using the Nonstandard Classification (Class 1: 6; Class 2: 2) and eight (19%) mutations using the Standard Classification (Class 1: 0, Class 2: 8) (Table 4 ; Supporting Information Table 3 ). Only one patient (pt 21) had an immediately targetable oncogenic variant in PIK3CA, p.His1047Arg (p.H1047R), (Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha), affecting exon 20 which increases its catalytic activity. This patient was a 79 year old female with deep 13.5 cm shoulder UPS treated with neo-adjuvant radiotherapy then resection who remains alive without disease at 42 months. Although other mutations were identified that are considered to be clinically relevant in other tumor types (PIK3CA p.Glu545Ala (p.E545A), FGFR1 p.Glu159_Asp160insGlu (E159_D160insE), NRAS p.Gln61Arg (Q61R)), none were immediately actionable for patients with STS. Other clinically relevant mutations were those with TP53 variants with initial reports suggesting its use a predictive biomarker of response to VEGFR inhibition in advanced STS patients. 27, 28 There was no statistical difference when comparing baseline characteristics [age or primary tumor characteristics (depth, stage, grade, maximum tumor size)] between those with identified genetic aberrations and those without.
Outcomes
After a median follow-up of 46.3 months (range, 1.3-281.9), 31 patients died of disease and 42 patients showed no evidence of disease, no patients were alive with persistent/recurrent, 14 patients died from other reasons and one patient's clinical details were unknown. The one-, two-and five-year overall survival for the entire group was 79.9%, 67.9% and 50.1% respectively and for those with localized disease was 81.0%, 77.1% and 68.7% respectively. There were no statistical differences in survival outcomes seen between major histological subgroups (e.g. UPS versus MFS versus Other) or by the presence/absence of a somatic mutation (Fig. 2) .
In patients with localized disease, using univariate analysis, advanced age was associated with inferior survival outcomes (p < 0.001) with a trend seen in patients with positive margins (p 5 0.09), maximum size (p 5 0.15) and by stage (p 5 0.15) ( Table 5 ). In multivariate analysis, for those with localized disease, inferior survival outcomes were seen in those with advanced age (p < 0.001), by stage (p 5 0.05) and by positive margins (p 5 0.02) ( Table 5) .
DISCUSSION
The biologic heterogeneity of STS makes investigation into specific subtypes crucial for improving outcomes in this rare disease. One of the most common subtypes of STS is UPS previously known as MFH. The difficulty in investigating this group stems from it being a diagnosis of exclusion-based on the absence of disease-defining morphologic, immunohistochemical and/or molecular characteristics and is presumably heterogeneous in composition. The classification of this entity is critical as it may change prognosis. In a study by Fletcher et al. 84 of 100 tumors that were re-interrogated after a diagnosis of MFH (old classification for UPS) showed evidence of a specific line of differentiation and that this was clinically meaningful (e.g. worse outcomes for tumors with myogenic differentiation). 6 These findings are similar to an additional study showing that 63% of previously classified MFH were able to be re-categorized to other specific sarcoma subgroups using morphological, immunohistochemical and ultrastructural criteria. 5 In our study, rigorous re-evaluation of the pathology of tumors previously classified as MFH/UPS 
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resulted in re-categorization to UPS in 20% and undifferentiated histologies in 30%. In contrast to the study by Fletcher, 6 we did not demonstrate worse outcomes when compared between histological subgroups. Although characterized by complex patternless genetic alterations, and cytogenetically aneuploid, 29 little information is available with regards to the specific genomic landscape of UPS. Growth factor-signaling in STS is thought to occur through two main pathways: the RAS/MAPK and the PI3K/ mTOR pathway. 30 Of note, hyperactivation of the RAS/ MAPK pathway is associated with increasing aggressiveness of UPS. 15 In this series, we screened 88 patients with a historical diagnosis of UPS and identified 42% of patients with MFS and 22% of patients with UPS having an identifiable somatic mutation on a targeted panel. Unfortunately, this has led to only a minority of clinically actionable mutations when divided according to our somatic variant classification scheme. 25 A solitary mutation that was clearly actionable (PIK3CA) was identified in a single patient with MFS. In addition, mutations in TP53 were identified that may serve as predictive biomarkers to lack of response to VEGFR inhibition. In comparison to the study from Serrano et al. 15 where activating mutations in the RAS/MAPK and PI3K/mTOR pathway were not identified in UPS, we identified a solitary mutation in PIK3CA p.His1047Arg (p.H1047R). This is similar to the report by Movva et al. which also identified PIK3CA mutations in 5.5% of 166 patients with UPS. 18 Early phase I studies of PIK3CA inhibitors have shown response rates in PIK3CA p.His1047Arg (p.H1047R), 31, 32 however clinical interpretation is difficult given the mixture of combination regimens and scheduling. In addition, emerging evidence has questioned whether mTOR inhibitors are active in tumors with PIK3CA mutations. 33, 34 In contrast to our study, a single KRAS p.Ala146Val (p.A146V) mutation was identified by Serrano et al. 15 thus supporting the concept of infrequent activation of RAS genes in UPS. [35] [36] [37] In addition, MET protein expression has been described in UPS and angiosarcoma bringing further weight for the investigation of MET inhibitors in these subgroups. 38 However, the MET mutation described in our patient cohort p.Glu168Asp (p.E168D) was likely a benign germline variant according to the ClinVar database. 39 Of note, the biological relevance of genes analyzed on our targeted panel is unclear. Gene analysis studies have shown that genes involved in motility, adhesion and proteolysis (e.g RAB32, PLAU, MSN, RUNX1 and DSC2) are particularly upregulated in MFH, 40 although these gene sets were not included in our targeted panel.
TP53 mutations were identified in 30% of patients with MFS and in 22% of patients with UPS which is similar to 
other reports of p53 pathway inactivation in this entity. 14, 18, 41 Part of the difficulty in classifying the clinical relevance of identified variants seen in this study stems from the limited data specific to genomic characterization of STS. Some recent unvalidated data have suggested that TP53 status may predict response to VEGFR inhibition. 27, 28 Koehler et al. 27 retrospectively reviewed 19 cases of STS treated with pazopanib (with only one case of UPS) and found that the PFS for patients with TP53 mutations was significantly increased compared to those with TP53 wild-type (208 vs 136 days, p values 5 0.036). As this was only a small, single-institution, retrospective study, it is unclear whether this finding will be validated in larger correlative studies. The phase 1 study by Fu et al. 28 combined a histone deacetylase inhibitor (vorinostat) with pazopanib and although the combination did not lead to antitumor activity in isolation, when stratified by TP53 status, patients with TP53-mutated cancers had some minor prolongation of PFS (3.5 vs 2.0 months, p values 5 0.042). Of note, in our cohort, no survival or clinical differences were identified when stratified between TP53-mutated and nonmutated samples.
Genomic-based personalized medicine is predicated on the ability to identify driver mutations and block these biological pathways using existing drugs via on-label or off label-prescribing, or via matching to phase 1 studies. 42 The allure of identifying target-drug matching is with the hope that targeted therapies may improve outcomes in the setting of precision medicine. Preliminary nonrandomized data have suggested that using a genomic matching approach may improve outcome, 43, 44 however more recent data have questioned this concept. 45 In STS, targeted therapies with established therapeutic potential include imatinib and sunitinib in GIST/dermatofibrosarcoma pruteberans and pazopanib in nonadipocytic sarcomas. Using targeted agents in UPS is relatively unknown as existing data are difficult to interpret given the limited size seen in this specific subgroup. For example, the PALETTE study, which investigated 800 mg of pazopanib versus placebo for patients postanthracyclinesbased chemotherapy, showed clinical benefit in a variety of STS subtypes, 46 although very few patients were classified with UPS. Subsequently limited reports have been show some limited effectiveness specific to the UPS subgroup. 47, 48 Other targeted agents have shown lack of significant activity in UPS with 0 of 14 responses seen with sorafenib, 49 0 of 8 patients using temsirolimus 50 and a partial response was seen in one of two patients using RAF/MEK inhibition. 51 Evolving investigations into genomic characterization, such as TP53 status, 27, 28 may further stratify those who may potentially gain greater benefit. In addition, outside the area of target-drug matching, preliminary reports have shown clinical utility in UPS using pembrolizumab, 52 with 4 of 10 patients achieving complete or partial responses and an additional three patients with stable disease. In this study, 52 PD-L1 expression via IHC and baseline infiltrating cytotoxic T cells correlated with response in UPS, however further confirmatory biomarker analysis is still required.
There are clear limitations of this study. Firstly, this is a retrospective review of patients with a historical diagnosis of UPS with a mixture of localized and metastatic disease without the inclusion of matched germline control DNAs. In addition, given cost constraints and using a pragmatic approach, a targeted cancer panel was used, thus the results may not be generalizable to broader panel and/or whole exome/genome sequencing. The low frequency of actionable mutations is keeping with other reports of targeted panels in sarcoma 18 thus future studies should be conducted using broader panels limited to relapsed patients in order to address the clinical utility target drug matching in these patients. In addition, other factors could be investigated such as copy number variations, cryptic rearrangements, translocations, immunoprofiling and epigenetic changes which were not assessed in our study. Nevertheless, with the falling costs and access to high-throughput technology, accessibility to NGS has exponentially improved to investigate genomic alterations for patients with STS. However, given the limited clinically actionable mutations identified, this study does not support the routine use of sequencing for UPS using a targeted panel outside of clinical trials. Further dedicated research protocols in UPS will be required to analyze deeper biological pathways that may translate into therapeutic benefit for these poor prognosis tumors.
